Topline results were announced from a phase 3 study assessing the immune response following coadministration of Arexvy and Shingrix.

Adults also need vaccines to protect against diseases like influenza, shingles, and pneumonia, especially susceptible individuals such as those with chronic diseases and healthcare workers.

Data from a late-stage study shows that co-administering GSK's RSV and Shingles vaccines together was as effective as giving each separately.

Closer takes a look at five vaccines you should get after you turn 50 to help protect against illness. Shingles: “The first ...

The latest research suggests that the recombinant shingles vaccine may offer additional benefits. It appears to reduce the ...

COVID-19 (coronavirus) and RSV vaccines for people with Crohn's or Colitis, the two main form of Inflammatory Bowel Disease, ...

GSK has revised its annual vaccine sales forecast following new guidance on RSV from the CDC. But new evidence offers new ...

If approved, the co-administration of Arexvy and Shingrix could provide a more convenient vaccination regimen for patients ...

GSK (GSK) reached the main goal in a Phase 3 trial for its RSV shot, Arexvy co--administered with Shingles vaccine Shingrix.

GSK plc (GSK, GSK.L) announced positive topline data from the phase 3 trial in adults 50 years and older evaluating the ...

In the study, co-administration of GSK's RSV vaccine Arexvy and shingles shot Shingrix elicited non-inferior immune responses ...

GSK released data from a Phase 3 trial evaluating the co-administration of Arexvy and Shingrix vaccines in adults 50+. The ...